SV2011003939A - Piridiloxi-indoles inhibidores del vegf-r2 y uso de los mismos para el tratamiento de enfermedades - Google Patents
Piridiloxi-indoles inhibidores del vegf-r2 y uso de los mismos para el tratamiento de enfermedadesInfo
- Publication number
- SV2011003939A SV2011003939A SV2011003939A SV2011003939A SV2011003939A SV 2011003939 A SV2011003939 A SV 2011003939A SV 2011003939 A SV2011003939 A SV 2011003939A SV 2011003939 A SV2011003939 A SV 2011003939A SV 2011003939 A SV2011003939 A SV 2011003939A
- Authority
- SV
- El Salvador
- Prior art keywords
- diseases
- treatment
- formula
- piridyloxi
- indoles
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
COMPUESTOS ORGÁNICOS NOVEDOSOS DE LA FÓRMULA (I): (VER FORMULA); Y A SU USO EN EL TRATAMIENTO DEL CUERPO ANIMAL O HUMANO, A LAS COMPOSICIONES FARMACÉUTICAS QUE COMPRENDEN UN COMPUESTO DE LA FÓRMULA I, Y AL USO DE UN COMPUESTO DE LA FÓRMULA I PARA LA PREPARACIÓN DE COMPOSICIONES FARMACÉUTICAS PARA UTILIZARSE EN EL TRATAMIENTO DE ENFERMEDADES DEPENDIENTES DE LA CINASA DE PROTEÍNA, EN ESPECIAL DE ENFERMEDADES PROLIFERATIVAS, TAL COMO EN EL TRATAMIENTO DE ENFERMEDADES TUMORALES Y ENFERMEDADES NEOVASCULARES OCULARES
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US20124308P | 2008-12-09 | 2008-12-09 | |
| US23334109P | 2009-08-12 | 2009-08-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SV2011003939A true SV2011003939A (es) | 2011-07-28 |
Family
ID=42034535
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SV2011003939A SV2011003939A (es) | 2008-12-09 | 2011-06-09 | Piridiloxi-indoles inhibidores del vegf-r2 y uso de los mismos para el tratamiento de enfermedades |
Country Status (39)
| Country | Link |
|---|---|
| US (6) | US8242125B2 (es) |
| EP (1) | EP2376478B1 (es) |
| JP (1) | JP5580330B2 (es) |
| KR (1) | KR101345956B1 (es) |
| CN (2) | CN103193773B (es) |
| AR (1) | AR074499A1 (es) |
| AU (1) | AU2009326110B9 (es) |
| BR (1) | BRPI0922552A2 (es) |
| CA (1) | CA2745922C (es) |
| CL (1) | CL2011001378A1 (es) |
| CO (1) | CO6382119A2 (es) |
| CR (1) | CR20110270A (es) |
| CU (1) | CU24097B1 (es) |
| CY (1) | CY1119091T1 (es) |
| DK (1) | DK2376478T3 (es) |
| EA (1) | EA019681B1 (es) |
| EC (1) | ECSP11011113A (es) |
| ES (1) | ES2633959T3 (es) |
| HN (1) | HN2011001593A (es) |
| HR (1) | HRP20171075T1 (es) |
| HU (1) | HUE035292T2 (es) |
| IL (1) | IL213068A (es) |
| JO (1) | JO3265B1 (es) |
| LT (1) | LT2376478T (es) |
| MX (1) | MX2011006093A (es) |
| MY (1) | MY155649A (es) |
| NZ (2) | NZ601656A (es) |
| PE (1) | PE20110835A1 (es) |
| PL (1) | PL2376478T3 (es) |
| PT (1) | PT2376478T (es) |
| RS (1) | RS56076B1 (es) |
| SG (1) | SG171784A1 (es) |
| SI (1) | SI2376478T1 (es) |
| SV (1) | SV2011003939A (es) |
| TN (1) | TN2011000263A1 (es) |
| TW (1) | TWI429640B (es) |
| UY (1) | UY32302A (es) |
| WO (1) | WO2010066684A2 (es) |
| ZA (1) | ZA201103759B (es) |
Families Citing this family (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2350075B1 (en) | 2008-09-22 | 2014-03-05 | Array Biopharma, Inc. | Substituted imidazo[1,2b]pyridazine compounds as trk kinase inhibitors |
| AR077468A1 (es) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
| AU2011322597B2 (en) * | 2010-10-27 | 2015-09-10 | Novartis Ag | Dosing regimes for the treatment of ocular vascular disease |
| CN102786469B (zh) * | 2011-05-18 | 2016-09-14 | 中国医学科学院药物研究所 | 邻吡啶酰肼衍生物及其制法和药物组合物与用途 |
| EA027113B1 (ru) * | 2012-05-04 | 2017-06-30 | Новартис Аг | Регуляторы пути комплемента и их применение |
| US9056874B2 (en) | 2012-05-04 | 2015-06-16 | Novartis Ag | Complement pathway modulators and uses thereof |
| KR101315227B1 (ko) * | 2012-05-30 | 2013-10-07 | 엘지디스플레이 주식회사 | 터치스크린 일체형 표시장치 및 그 구동 방법 |
| WO2014002051A2 (en) * | 2012-06-28 | 2014-01-03 | Novartis Ag | Complement pathway modulators and uses thereof |
| WO2014002053A1 (en) * | 2012-06-28 | 2014-01-03 | Novartis Ag | Pyrrolidine derivatives and their use as complement pathway modulators |
| JP6155332B2 (ja) * | 2012-06-28 | 2017-06-28 | ノバルティス アーゲー | ピロリジン誘導体、および補体経路調節因子としてのその使用 |
| ES2712190T3 (es) * | 2012-06-28 | 2019-05-09 | Novartis Ag | Moduladores de la vía del complemento y sus usos |
| WO2014002057A1 (en) * | 2012-06-28 | 2014-01-03 | Novartis Ag | Pyrrolidine derivatives and their use as complement pathway modulators |
| EP2867229B1 (en) * | 2012-06-28 | 2017-07-26 | Novartis AG | Pyrrolidine derivatives and their use as complement pathway modulators |
| EA201590200A1 (ru) * | 2012-07-12 | 2015-08-31 | Новартис Аг | Модуляторы пути активации комплемента и их применение |
| CN103570616B (zh) * | 2012-07-18 | 2017-10-20 | 中国医学科学院药物研究所 | N′‑直链烷酰基邻吡啶酰肼衍生物及其制法和药物组合物与用途 |
| CN105229003B (zh) | 2013-03-14 | 2017-03-15 | 诺华股份有限公司 | 作为补体因子b抑制剂用于治疗眼科疾病的2‑(1h‑吲哚‑4‑基甲基)‑3h‑咪唑并[4,5‑b]吡啶‑6‑甲腈衍生物 |
| WO2014154173A1 (zh) * | 2013-03-28 | 2014-10-02 | 广州康睿生物医药科技有限公司 | 一种抗血管新生化合物 |
| US20150018376A1 (en) | 2013-05-17 | 2015-01-15 | Novartis Ag | Pyrimidin-4-yl)oxy)-1h-indole-1-carboxamide derivatives and use thereof |
| US10174006B2 (en) * | 2013-06-06 | 2019-01-08 | Novartis Ag | Topical aqueous ophthalmic compositions containing a 1H-indole-1-carboxamide derivative and use thereof for treatment of ophthalmic disease |
| JO3425B1 (ar) | 2013-07-15 | 2019-10-20 | Novartis Ag | مشتقات البابيريدينيل-اندول واستخدامها كعامل متمم لمثبطات b |
| JP6522502B2 (ja) | 2013-07-29 | 2019-05-29 | 協和発酵キリン株式会社 | Ｗｎｔシグナル阻害剤 |
| US9676728B2 (en) | 2013-10-30 | 2017-06-13 | Novartis Ag | 2-benzyl-benzimidazole complement factor B inhibitors and uses thereof |
| JP6248269B2 (ja) * | 2014-02-06 | 2017-12-20 | 株式会社Ｊｏｌｅｄ | 表示装置 |
| JP2017206437A (ja) * | 2014-08-18 | 2017-11-24 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ４−アミノピリジン誘導体 |
| WO2016137506A1 (en) * | 2015-02-27 | 2016-09-01 | Nantbioscience, Inc. | Pyrimidine derivatives as kinase inhibitors and their therapeutical applications |
| WO2017003862A1 (en) * | 2015-07-01 | 2017-01-05 | Pharmakea, Inc. | Lysyl oxidase-like 2 inhibitors and uses thereof |
| EP3322706B1 (en) | 2015-07-16 | 2020-11-11 | Array Biopharma, Inc. | Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors |
| TN2018000138A1 (en) | 2015-10-26 | 2019-10-04 | Array Biopharma Inc | Point mutations in trk inhibitor-resistant cancer and methods relating to the same |
| JP6857651B2 (ja) | 2015-11-06 | 2021-04-14 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | Ｃｎｓ疾患の処置に有用なインドリン−２−オン誘導体 |
| EP3371174B1 (en) | 2015-11-06 | 2021-03-17 | H. Hoffnabb-La Roche Ag | Indolin-2-one derivatives |
| JP6857653B2 (ja) | 2015-11-06 | 2021-04-14 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | Ｃｎｓ及び関連障害の治療において使用するためのインドリン−２−オン誘導体 |
| CR20180255A (es) | 2015-11-06 | 2018-06-22 | Hoffmann La Roche | Derivados de indolin-2-ona |
| RS65988B1 (sr) | 2016-04-04 | 2024-10-31 | Loxo Oncology Inc | Postupak lečenja pedijatrijskih karcinoma |
| US10045991B2 (en) | 2016-04-04 | 2018-08-14 | Loxo Oncology, Inc. | Methods of treating pediatric cancers |
| HUE068971T2 (hu) | 2016-04-04 | 2025-02-28 | Loxo Oncology Inc | (S)-N-(5-((R)-2-(2,5-difluorofenil)-pirrolidin-1-il)-pirazolo[1,5-A]pirimidin-3-il) -3-hidroxipirrolidin-1-karboxamid folyékony készítményei |
| SI3458456T1 (sl) | 2016-05-18 | 2021-04-30 | Loxo Oncology, Inc. | Priprava (S)-N-(5-((R)-2-(2,5-difluorofenil) pirolidin-1-il) pirazolo (1,5-A) pirimidin-3-il)-3-hidroksipirolidin-1-karboksamida |
| TWI704148B (zh) | 2016-10-10 | 2020-09-11 | 美商亞雷生物製藥股份有限公司 | 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物 |
| JOP20190077A1 (ar) | 2016-10-10 | 2019-04-09 | Array Biopharma Inc | مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret |
| JP2019534269A (ja) | 2016-10-14 | 2019-11-28 | ノバルティス アーゲー | Ｃｓｆ−１ｒの阻害剤を使用して眼疾患を治療するための方法 |
| JOP20190092A1 (ar) | 2016-10-26 | 2019-04-25 | Array Biopharma Inc | عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها |
| WO2018136663A1 (en) | 2017-01-18 | 2018-07-26 | Array Biopharma, Inc. | Ret inhibitors |
| CN110267960B (zh) | 2017-01-18 | 2022-04-26 | 阿雷生物药品公司 | 作为RET激酶抑制剂的取代的吡唑并[1,5-a]吡嗪化合物 |
| JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
| JOP20190245A1 (ar) | 2017-04-20 | 2019-10-15 | Novartis Ag | أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط |
| TWI812649B (zh) | 2017-10-10 | 2023-08-21 | 美商絡速藥業公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物 |
| TWI791053B (zh) | 2017-10-10 | 2023-02-01 | 美商亞雷生物製藥股份有限公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物 |
| TW201938169A (zh) | 2018-01-18 | 2019-10-01 | 美商亞雷生物製藥股份有限公司 | 作為RET激酶抑制劑之經取代吡唑并[3,4-d]嘧啶化合物 |
| WO2019143994A1 (en) | 2018-01-18 | 2019-07-25 | Array Biopharma Inc. | Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors |
| CN111971286B (zh) | 2018-01-18 | 2023-04-14 | 阿雷生物药品公司 | 作为RET激酶抑制剂的取代的吡咯并[2,3-d]嘧啶化合物 |
| CN108586454B (zh) * | 2018-02-13 | 2021-02-26 | 沈阳药科大学 | 四氢吡啶并[4,3-d]嘧啶类衍生物及其用途 |
| CN110386892B (zh) * | 2018-04-16 | 2020-08-18 | 新发药业有限公司 | 一种4-氟-5-羟基-2-甲基-1h-吲哚的制备方法 |
| CN110483482A (zh) * | 2018-05-15 | 2019-11-22 | 北京诺诚健华医药科技有限公司 | 吲哚啉-1-甲酰胺类化合物、其制备方法及其在医药学上的应用 |
| KR102653681B1 (ko) | 2018-07-31 | 2024-04-03 | 록쏘 온콜로지, 인코포레이티드 | (s)-5-아미노-3-(4-((5-플루오로-2-메톡시벤즈아미도)메틸)페닐)-1-(1,1,1-트리플루오로프로판-2-일)-1h-피라졸-4-카르복스아미드의분무-건조된 분산물 및 제제 |
| ES2922314T3 (es) | 2018-09-10 | 2022-09-13 | Array Biopharma Inc | Compuestos heterocíclicos condensados como inhibidores de cinasa RET |
| WO2020131674A1 (en) | 2018-12-19 | 2020-06-25 | Array Biopharma Inc. | 7-((3,5-dimethoxyphenyl)amino)quinoxaline derivatives as fgfr inhibitors for treating cancer |
| EP3898626A1 (en) | 2018-12-19 | 2021-10-27 | Array Biopharma, Inc. | Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases |
| KR20210151818A (ko) * | 2019-04-12 | 2021-12-14 | 내셔날 헬스 리서치 인스티튜트 | 치료 용도를 위한 키나제 억제제로서의 헤테로사이클릭 화합물 |
| MX2022007171A (es) | 2019-12-27 | 2022-08-22 | Schroedinger Inc | Compuestos cíclicos y métodos de uso de estos. |
| WO2022033472A1 (zh) * | 2020-08-11 | 2022-02-17 | 河南迈英诺医药科技有限公司 | Fgfr抑制剂化合物及其用途 |
| EP4211140A1 (en) | 2020-09-10 | 2023-07-19 | Schrödinger, Inc. | Heterocyclic pericondensed cdc7 kinase inhibitors for the treatment of cancer |
| EP4284804A1 (en) | 2021-01-26 | 2023-12-06 | Schrödinger, Inc. | Tricyclic compounds useful in the treatment of cancer, autoimmune and inflammatory disorders |
| TW202300150A (zh) | 2021-03-18 | 2023-01-01 | 美商薛定諤公司 | 環狀化合物及其使用方法 |
| IL314186A (en) | 2022-01-24 | 2024-09-01 | Novartis Ag | Spirocyclic piperidinyl derivatives as complement factor b inhibitors and uses thereof |
| US20250223277A1 (en) | 2022-04-01 | 2025-07-10 | Novartis Ag | Complement factor b inhibitors and uses thereof |
| WO2025059027A1 (en) | 2023-09-11 | 2025-03-20 | Schrödinger, Inc. | Cyclopenta[e]pyrazolo[1,5-a]pyrimidine derivatives as malt1 inhibitors |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2001231710A1 (en) | 2000-02-09 | 2001-08-20 | Novartis Ag | Pyridine derivatives inhibiting angiogenesis and/or vegf receptor tyrosine kinase |
| HU230302B1 (hu) * | 2000-10-20 | 2015-12-28 | Eisai R&D Management Co., Ltd. | Nitrogéntartalmú aromás származékok és ezeket tartalmazó gyógyászati készítmények |
| GB0126902D0 (en) | 2001-11-08 | 2002-01-02 | Novartis Ag | Organic compounds |
| PE20040522A1 (es) * | 2002-05-29 | 2004-09-28 | Novartis Ag | Derivados de diarilurea dependientes de la cinasa de proteina |
| MXPA05001536A (es) | 2002-08-30 | 2005-04-19 | Eisai Co Ltd | Derivados aromaticos que contienen nitrogeno. |
| AR041992A1 (es) * | 2002-11-06 | 2005-06-08 | Smithkline Beecham Corp | Compuesto de piridinil benzoheterociclico, composicion farmaceutica que lo comprende y su uso para prepararla |
| SE0302324D0 (sv) | 2003-08-28 | 2003-08-28 | Astrazeneca Ab | Novel compounds |
| PE20060664A1 (es) * | 2004-09-15 | 2006-08-04 | Novartis Ag | Amidas biciclicas como inhibidores de cinasa |
| GB0420520D0 (en) * | 2004-09-15 | 2004-10-20 | Novartis Ag | Organic compounds |
| GB0421525D0 (en) * | 2004-09-28 | 2004-10-27 | Novartis Ag | Inhibitors of protein kineses |
| DOP2006000051A (es) | 2005-02-24 | 2006-08-31 | Lilly Co Eli | Inhibidores de vegf-r2 y métodos |
| GT200600411A (es) * | 2005-09-13 | 2007-05-21 | Novartis Ag | Combinaciones que comprenden un inhibidor del receptor del factor de crecimiento endotelial vascular |
| EP2574340A3 (en) | 2006-04-07 | 2013-04-17 | Novartis AG | Combination comprising a pyrimidylaminobenzamide compound and a THR315LLEe kinase inhibitor |
| US20090176778A1 (en) | 2007-08-10 | 2009-07-09 | Franz Ulrich Schmitz | Certain nitrogen containing bicyclic chemical entities for treating viral infections |
| WO2009036066A1 (en) | 2007-09-10 | 2009-03-19 | Curis, Inc. | Vegfr inhibitors containing a zinc binding moiety |
| TWI440638B (zh) | 2007-10-30 | 2014-06-11 | Otsuka Pharma Co Ltd | 雜環化合物及其藥學組成物 |
-
2009
- 2009-12-06 JO JOP/2009/0466A patent/JO3265B1/ar active
- 2009-12-07 EA EA201100873A patent/EA019681B1/ru not_active IP Right Cessation
- 2009-12-07 HU HUE09774876A patent/HUE035292T2/en unknown
- 2009-12-07 AR ARP090104731A patent/AR074499A1/es unknown
- 2009-12-07 ES ES09774876.8T patent/ES2633959T3/es active Active
- 2009-12-07 MY MYPI2011002414A patent/MY155649A/en unknown
- 2009-12-07 MX MX2011006093A patent/MX2011006093A/es active IP Right Grant
- 2009-12-07 CA CA2745922A patent/CA2745922C/en not_active Expired - Fee Related
- 2009-12-07 AU AU2009326110A patent/AU2009326110B9/en not_active Ceased
- 2009-12-07 KR KR1020117015822A patent/KR101345956B1/ko not_active Expired - Fee Related
- 2009-12-07 BR BRPI0922552A patent/BRPI0922552A2/pt not_active IP Right Cessation
- 2009-12-07 CU CU2011000129A patent/CU24097B1/es active IP Right Grant
- 2009-12-07 PE PE2011001180A patent/PE20110835A1/es not_active Application Discontinuation
- 2009-12-07 US US12/632,396 patent/US8242125B2/en active Active
- 2009-12-07 DK DK09774876.8T patent/DK2376478T3/en active
- 2009-12-07 CN CN201310101393.0A patent/CN103193773B/zh active Active
- 2009-12-07 SG SG2011036878A patent/SG171784A1/en unknown
- 2009-12-07 NZ NZ601656A patent/NZ601656A/xx not_active IP Right Cessation
- 2009-12-07 EP EP09774876.8A patent/EP2376478B1/en active Active
- 2009-12-07 LT LTEP09774876.8T patent/LT2376478T/lt unknown
- 2009-12-07 CN CN200980156323.7A patent/CN102307870B/zh active Active
- 2009-12-07 PL PL09774876T patent/PL2376478T3/pl unknown
- 2009-12-07 HR HRP20171075TT patent/HRP20171075T1/hr unknown
- 2009-12-07 PT PT97748768T patent/PT2376478T/pt unknown
- 2009-12-07 RS RS20170576A patent/RS56076B1/sr unknown
- 2009-12-07 SI SI200931684A patent/SI2376478T1/sl unknown
- 2009-12-07 JP JP2011540046A patent/JP5580330B2/ja active Active
- 2009-12-07 UY UY0001032302A patent/UY32302A/es not_active Application Discontinuation
- 2009-12-07 WO PCT/EP2009/066540 patent/WO2010066684A2/en not_active Ceased
- 2009-12-07 NZ NZ593030A patent/NZ593030A/xx not_active IP Right Cessation
- 2009-12-08 TW TW098141904A patent/TWI429640B/zh not_active IP Right Cessation
-
2011
- 2011-05-23 CR CR20110270A patent/CR20110270A/es unknown
- 2011-05-23 ZA ZA2011/03759A patent/ZA201103759B/en unknown
- 2011-05-23 TN TN2011000263A patent/TN2011000263A1/fr unknown
- 2011-05-23 IL IL213068A patent/IL213068A/en not_active IP Right Cessation
- 2011-06-07 EC EC2011011113A patent/ECSP11011113A/es unknown
- 2011-06-08 CL CL2011001378A patent/CL2011001378A1/es unknown
- 2011-06-09 SV SV2011003939A patent/SV2011003939A/es unknown
- 2011-06-09 HN HN2011001593A patent/HN2011001593A/es unknown
- 2011-06-10 CO CO11072268A patent/CO6382119A2/es active IP Right Grant
-
2012
- 2012-06-05 US US13/488,760 patent/US8431584B2/en active Active
- 2012-09-13 US US13/613,062 patent/US8501756B2/en active Active
- 2012-09-13 US US13/613,019 patent/US8492393B2/en active Active
- 2012-09-13 US US13/613,053 patent/US8541432B2/en active Active
- 2012-09-13 US US13/613,034 patent/US8486954B2/en active Active
-
2017
- 2017-07-19 CY CY20171100772T patent/CY1119091T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SV2011003939A (es) | Piridiloxi-indoles inhibidores del vegf-r2 y uso de los mismos para el tratamiento de enfermedades | |
| ECSP077324A (es) | Amidas bicíclicas como inhibidores de cinasa | |
| CL2013003227A1 (es) | “compuestos derivados de indazol sustituidos, moduladores de la actividad de proteínas quinasas; proceso de obtención de ellos; método in vitro para inhibir proteínas quinasas; composición y combinación farmacéutica que los comprende; y su uso en el tratamiento del cáncer" pct | |
| GT201400009A (es) | 4-imidazopiridazin-1-il-benzamidas y 4-imidazotriazin-1-il-benzamidas como inhibidores de btk | |
| ECSP109935A (es) | Derivados de morfolino pirimidina utilizados en enfermedades relacionadas con mtor quinasa y/o pi3k | |
| CO6300957A2 (es) | Derivados de imidazo -[1,2,b]-piridazina para el tratamiento de enfermedad mediada por cinasa de tirosina c-met | |
| CO6390066A2 (es) | Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas | |
| SV2009003299A (es) | Derivados de dihidropiridina de utilidad como inhibidores de la proteina quinasa | |
| CR11455A (es) | Compuestos nuevos de hidrocarbono ciclico para el tratamiento de enfermedades | |
| DOP2012000299A (es) | 5-fluoro-1h-pirazolopiridinas sustituidas y su uso | |
| ECSP088974A (es) | Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3) | |
| ECSP109934A (es) | Compuesto - 946 | |
| CR20200334A (es) | Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas | |
| ECSP088973A (es) | Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3) | |
| CO6690816A2 (es) | Derivados de quinazolin-4(3h)-ona utilizados como inhibidores de pi3 cinasa | |
| CL2009001240A1 (es) | Compuestos derivados del acido l-glutamico y l-glutamina marcados con [f-18]; procedimiento de preparacion; composicion farmaceutica que comprende a los compuestos y su uso como agentes en el diagnostico de tumores. | |
| MX347927B (es) | Vitamina c y vitamina k libre de cromo, y composiciones de estas para tratar un estado o enfermedad en las que interviene nfkb. | |
| UY32829A (es) | Derivados de 3-heteroaril-metil-imidazo-[1,2-b]-pirididazin - 6 -ilo | |
| ECSP13012541A (es) | Combinaciones farmacéuticas | |
| GT201700220A (es) | Derivados de pirazol útiles como inhibidores de proteína activadora de 5-lipoxigenasa (flap) | |
| CL2013003556A1 (es) | Compuestos derivados de ftalazinona-pirrolo[3,2-d]pirimidin-carboxamida, inhibidoers de fosfodiesterasa tipo 4 y tipo 5; composcin farmaceutica que o comprende, combinacion fija, no fija y kit, uso del compuesto en la preparacion de un medicamento para trata enfermedaes de las vias respiratorias | |
| DOP2013000004A (es) | Agentes terapeuticos 976 | |
| AR081024A1 (es) | Asociacion de los inhibidores de la xantina oxidasa y la metformina y su uso | |
| CU20100004A7 (es) | Derivados de morfolino pirimidina utilizados en enfermedades relacionadas con mtor quinasa y/o pi3k | |
| CU20100003A7 (es) | Derivados trisustituídas de pirimidina para el tratamiento de enfermedades proliferativas |